5 completed, 2 withdrawn, 1 active not recruiting, 1 not yet recruiting. 2 Not applicable, 2 Phase 1, 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 2 | Completed 1, Withdrawn 1 |
| Phase 1 | 2 | Active not recruiting 1, Completed 1 |
| Phase 3 | 2 | Completed 2 |
| Phase 2 | 1 | Not yet recruiting 1 |
Follow Limb-girdle muscular dystrophy, type 2C: new trials by email Literature Review of Limb-girdle muscular dystrophy, type 2C trials Research Report on Limb-girdle muscular dystrophy, type 2C
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Labyrinthin Vaccination in Veterans With Lung Adenocarcinoma LabVax 3(22)-23 and GM-CSF (adjuvant) in combination with pembrolizumab - Type and Grade of Toxicities, Demographic and Background Characteristics, Advanced, Metastatic, Recurrent Adenocarcinoma and Malignant Solid Neoplasm | Phase 2 | Not yet recruiting | VA Office of Research and Development | 30 | 2026-12-01 | 2026-10-06 |
| ATA-200 Gene Therapy Trial in Patients With LGMDR5 ATA-200 - LGMD2C | Phase 1 | Active not recruiting | Atamyo Therapeutics | 4 | 2025-02-15 | 2026-01-29 |
| Natural History Study in Patients With LGMDR5/2c Gamma-sarcoglycanopathy | Withdrawn | Atamyo Therapeutics | 2025-01-10 | 2025-10-06 | ||
| Long-Term Development of Muscular Dystrophy Outcome Assessments LGMD1B, LGMD1C | Recruiting | Virginia Commonwealth University | 1000 | 2023-10-18 | 2025-11-18 | |
| Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma lenalidomide, Placebo, Rituximab - Lymphoma, Large B-Cell, Diffuse | Phase 3 | Completed | Celgene | 570 | 2015-02-17 | 2023-06-22 |
| Stem Cell Quantification In Peripheral Blood After Hyperbaric Oxygen Therapy Treatments Hyperbaric Oxygen Treatment - Changes in Peripheral Blood Population Numbers and Type. | Unknown | Restorix Research Institute, LLLP | 8 | 2012-12-01 | 2012-12-04 | |
| What Makes Exercise Feel More Difficult to Women With and Without Type 2 Diabetes Type 2 Diabetes | Completed | University of Colorado, Denver | 99 | 2008-05-01 | 2022-10-14 | |
| Influence of Endothelial Function on Central and Peripheral Causes Of Exercise Impairment in Type 2 Diabetes Exercise program, Ascorbic Acid (Vitamin C) - Type 2 Diabetes | Not applicable | Completed | University of Colorado, Denver | 47 | 2008-05-01 | 2023-07-12 |
| Clinical Study of AAV1-gamma-sarcoglycan Gene Therapy for Limb Girdle Muscular Dystrophy Type 2C AAV1-gamma-sarcoglycan vector injection - Limb Girdle Muscular Dystrophy Type 2C, Gamma-sarcoglycanopathy | Phase 1 | Completed | Genethon | 9 | 2006-11-01 | 2011-04-29 |
| Safety and Tolerability of Frovatriptan to Prevention of Menstrually Associated Migraine (MAM) Headaches Frovatriptan 2.5 mg - Migraine | Phase 3 | Completed | Endo USA Inc., a Keenova Therapeutics Company | 550 | 2003-12-01 | 2024-01-02 |
| Impact of Clinical Pharmacy Services on Medication Cost and Hospitalization Rates in Hemodialysis Patients Behavioral Patient care - End Stage Renal Disease | Not applicable | Withdrawn | University of New Mexico | 2003-01-01 | 2024-03-13 |
Diabetes Mellitus (2) · Diabetes Mellitus, Type 2 (2) · Motor Activity (2) · Adenocarcinoma (1) · Carcinoma (1) · Kidney Failure, Chronic (1) · Limb-Girdle Muscular Dystrophy, Type 1G (1) · Limb-girdle muscular dystrophy type 2A (1) · Limb-girdle muscular dystrophy type 2F (1) · Limb-girdle muscular dystrophy, type 1B (1) · Limb-girdle muscular dystrophy, type 2B (1) · Limb-girdle muscular dystrophy, type 2E (1) · Lymphoma, Large B-Cell, Diffuse (1) · Migraine Disorders (1)
Nervous System Diseases (3) · Behavior (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Disease Attributes (2) · Endocrine System Diseases (2) · Genetic Diseases, Inborn (2) · Glucose Metabolism Disorders (2) · Metabolic Diseases (2) · Neoplasms (2) · Nutritional and Metabolic Diseases (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Brain Diseases (1) · Cardiomyopathies (1) · Cardiovascular Diseases (1)
Adjuvants, Pharmaceutic (1) · Ascorbic Acid (1) · Cyclophosphamide (1) · Doxorubicin (1) · Exercise (1) · Granulocyte-Macrophage Colony-Stimulating Factor (1) · Lenalidomide (1) · Oxygen (1) · Prednisone (1) · Resistance Training (1) · Rituximab (1) · Vincristine (1) · frovatriptan (1) · pembrolizumab (1)
Atamyo Therapeutics (2) · University of Colorado, Denver (2) · Celgene (1) · Endo USA Inc., a Keenova Therapeutics Company (1) · Genethon (1) · Restorix Research Institute, LLLP (1) · University of New Mexico (1) · VA Office of Research and Development (1) · Virginia Commonwealth University (1)
United States (7) · France (3) · Australia (1) · Belgium (1) · Canada (1) · China (1) · Czechia (1) · Germany (1) · Hungary (1) · Ireland (1) · Israel (1) · Italy (1) · Japan (1) · Netherlands (1) · New Zealand (1)
Amy B Pai, Pharm.D (1) · Amy Huebschmann, MD (1) · Anne MacGregor, DIPM MFFP (1) · Judith G Regensteiner, PhD (1) · Nicholas Johnson, MD (1) · Serge Herson, Prof (1) · Tianhong Li, MD (1)
PMID 19788471, PMID 26464803, PMID 29456629, PMID 33621109, PMID 39563886
UL1TR000154 (1)